Editor's Choice
CRISPRing the microbiome is just around the corner
To date, CRISPR enzymes have been used to edit the genomes of one type of cell at a time: They cut, delete or add genes to a specific kind of cell within a tissue or […]
Pharma & Human Health
Biotech Showcase
Bringing the Transformative Power of Synthetic Biology to Medicine
This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 […]
Pharma & Human Health
Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with ASD
Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological conditions, today announced that the first subjects have successfully received their first dose in the company’s global Phase 2b clinical […]
Editor's Choice
Eligo Bioscience Announces Successful Outcome in US Patent Interference against SNIPR Biome
Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021, a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to […]
Finance
Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
Sanofi announced today it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, […]
Editor's Choice
Microbiome ‘editing’ for infectious disease and more: An overview of bacteriophage drug development
Microbiome-focused drug development is often thought of as the addition of beneficial strains or consortia of bacteria to specific sites in the body. Yet some drug products rather aim to take away elements or profoundly […]
Finance
Everimmune raises €5m to enter clinical phase in microbiome immuno-oncology
EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, today announces it has raised more than €5 million (approx. $6M) in a Series A funding from […]
Editor's Choice
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
Live biotherapeutic products (LBPs) are defined by the U.S. FDA as biological products that contain live organisms applicable to the prevention, treatment, or cure of a disease or condition (1). LBP therapies continue to attract […]
Pharma & Human Health
Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001
Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, announced positive results from a Phase 1 study of orally-administered NOV-001 in healthy volunteers. The Phase 1 study demonstrated the ability […]
Biotech Showcase
Engineering the Microbiome to Treat Skin Diseases
The skin microbiome plays a fundamental role in human health, protecting against pathogens and antigens, while bolstering cutaneous immunity. Imbalances in the skin microbiome (i.e. “dysbiosis”) are highly associated with severity of skin disease, […]
Pharma & Human Health
Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced positive topline results […]